JCI Q1 Earnings Call: New Leadership Emphasizes Operational Efficiency and Strategic Refocus

Building operations company Johnson Controls (NYSE:JCI) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 1.4% year on year to $5.68 billion. On top of that, next quarter's revenue guidance ($6.19 billion at the midpoint) was surprisingly good and 4.3% above what analysts were expecting. Its non-GAAP profit of $0.82 per share was 2.6% above analysts' consensus estimates.
Is now the time to buy JCI? Find out in our full research report (it's free).
Revenue: $5.68 billion vs analyst estimates of $5.64 billion (1.4% year-on-year growth, 0.7% beat)
Adjusted EPS: $0.82 vs analyst estimates of $0.80 (2.6% beat)
Revenue Guidance for Q2 CY2025 is $6.19 billion at the midpoint, above analyst estimates of $5.94 billion
Management reiterated its full-year Adjusted EPS guidance of $3.55 at the midpoint
Operating Margin: 10.2%, up from -6.8% in the same quarter last year
Organic Revenue rose 7% year on year (1.1% in the same quarter last year)
Market Capitalization: $67.71 billion
Johnson Controls' first quarter results were shaped by steady demand across its building solutions and applied HVAC businesses, underpinned by a sharp focus on operational execution. CEO Joakim Weidemanis, in his first earnings call since taking the helm, highlighted broad-based organic sales growth and margin expansion, attributing these gains to improved productivity, streamlined processes, and continued strength in service offerings. Weidemanis noted, 'Our record backlog and momentum in our recurring businesses continue to demonstrate broad-based and sustained demand for our differentiated solutions.' The company also reported enhanced working capital management and strong free cash flow, reflecting its ongoing efforts to deliver more predictable and consistent performance.
Looking forward, Johnson Controls' leadership signaled that the company's outlook is anchored by its record backlog, ongoing operational improvements, and a shift toward a more customer-centric organizational model. Weidemanis stated, 'We are building on a solid foundation, and I believe with more relentless focus on customers across our organization as well as on lean-enabled execution fundamentals, we will be able to drive accelerated value creation.' Management also cautioned that navigating tariffs and global uncertainties remains a challenge, but the company plans to leverage its long-cycle business structure, pricing strategies, and supply chain adjustments to mitigate potential impacts. Strategic priorities now include implementing lean methodologies and reassessing portfolio optimization for higher returns.
Management attributed quarterly growth to robust backlog expansion, operational efficiencies, and a reorganization designed to enhance customer focus and agility.
Backlog Expansion: The company reported a 12% increase in its order backlog, reaching $14 billion, driven by strong demand for its YORK HVAC systems and Metasys building automation platform. This provides multi-quarter revenue visibility and underpins management's confidence in future performance.
Operational Efficiencies: Margin improvements were supported by leaner operations, SKU reduction efforts, and an emphasis on waste elimination. Management described initiatives to simplify product offerings and optimize manufacturing and supply chain processes, aiming to unlock further cost savings.
Segment Reorganization: Johnson Controls transitioned to three geographically focused reporting segments, supported by global centers of functional excellence. This new structure is intended to foster customer intimacy, accelerate innovation, and clarify roles across the organization.
Service and Applied HVAC Growth: The service business continued to post high-single-digit organic growth, with especially strong performance in North America and Asia Pacific. Applied HVAC, which serves large infrastructure projects such as data centers, delivered more than 20% growth, reflecting both volume increases and product differentiation.
Tariff and Supply Chain Adaptation: Management acknowledged the challenge posed by new tariffs and outlined mitigation strategies, such as localizing supply chains, accelerating pricing actions, and enforcing contractual protections to minimize financial impact.
Management expects future growth to be shaped by lean operational initiatives, robust backlog execution, and proactive responses to external headwinds.
Lean Transformation Initiatives: CEO Joakim Weidemanis emphasized the rollout of lean business practices across operations, starting with targeted value streams and SKU rationalization. These efforts are expected to yield further productivity improvements and margin enhancement over time, though management noted the scale and complexity of the organization may delay full impact.
Portfolio Optimization and Customer Focus: The company is reassessing its portfolio, including fire and security offerings, for higher returns and strategic alignment. Management is prioritizing customer-centricity and data-driven decision making, with ongoing evaluation of which business areas and geographies offer the best opportunities for value creation.
Tariff and Inflation Risk Management: Johnson Controls is actively adjusting its pricing models and contractual terms to address inflation and tariff risks. The company's long-cycle business model and recurring service contracts provide some stability, but management cautioned that passing through higher costs may temporarily dampen margin expansion.
In the coming quarters, the StockStory team will be watching (1) the pace and effectiveness of lean transformation efforts across product and field operations, (2) whether backlog conversion and service attachment rates improve under the new organizational structure, and (3) how successfully Johnson Controls mitigates tariff and inflationary pressures through pricing and supply chain strategies. Progress in portfolio optimization and clarity on capital allocation priorities will also be key signposts for future performance.
Johnson Controls currently trades at a forward P/E ratio of 26.7×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

an hour ago

• Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

Yahoo

3 hours ago

• Yahoo

Retail Traders Just Sent This AI Health Stock Soaring 60%

Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.

Yahoo

4 hours ago

• Yahoo

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio